As We Inch Closer to a Vaccine, Approved-Treatments from Eli Lilly and Gilead Are Still Critical

Mere hours after Pfizer (PFE) announces a 90% effectiveness rate in its COVID-19 vaccine candidate the company’s been producing in conjunction with BioNTech (BNTX), Eli Lilly (LLY) shares positive news of its own on the coronavirus front. Late yesterday afternoon the drugmaker revealed its COVID-19 antibody treatment Bamlanivimab received emergency use authorization from the FDA

Read More ›

Market Overview